DRG Market Assessment reports

Clarivate Epidemiology’s coverage of coronary heart disease CHD comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the diagnosed prevalence…

Clarivate Epidemiology’s coverage of coronary heart disease (CHD) comprises epidemiological estimates of key patient populations in 14 mature and emerging pharmaceutical markets worldwide. We…

Clarivate Epidemiology’s coverage of coronary heart disease (CHD) comprises epidemiological estimates of key patient populations in 14 mature and emerging pharmaceutical markets worldwide. We…

Primary biliary cholangitis (PBC) is a rare autoimmune liver disease characterized by inflammation, progressive damage, and destruction of the interlobular bile ducts; this process is followed by…

Systemic lupus erythematosus (SLE) is an autoimmune disease that affects multiple organ systems of the body. SLE symptoms range from general malaise to serious CNS and renal manifestations…

Multiple well-established therapies are available to treat Crohn’s disease (CD). The mostly widely used biologics, the TNF-α inhibitors (e.g., Janssen / Merck’s Remicade, AbbVie / Eisai’s…

Chronic kidney disease (CKD) is caused by structural or functional abnormalities in the kidney that impair its ability to filter blood. RAAS inhibitors are cornerstones of CKD treatment. SGLT-2…

Clarivate Epidemiology’s coverage of chronic myeloid leukemia (CML) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and…

Clarivate Epidemiology’s coverage of uveitis comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy,…

Clarivate Epidemiology’s coverage of chronic myeloid leukemia comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and…

Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key chronic myeloid leukemia patient populations covering 171 countries…

The arrival of newer and more effective treatments in the U.S. psoriasis market is changing the treatment landscape and fueling competition for favorable coverage from MCOs. After years of…